A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

ClinicalTrials.gov ID: NCT00507507

Public ClinicalTrials.gov record NCT00507507. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B

Study identification

NCT ID: NCT00507507
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Gilead Sciences; Industry
Enrollment: 126 participants

Conditions and interventions

Conditions

Chronic Hepatitis B

Interventions

Tenofovir DF Drug
FTC Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 69 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2007
Primary completion: Jan 31, 2012
Completion: Jul 31, 2012
Last update posted: Jul 16, 2015

2007 – 2012

United States locations

U.S. sites: 10
U.S. states: 6
U.S. cities: 9

Facility	City	State	ZIP	Site status
Not listed	Los Angeles	California	90048	—
Not listed	San Diego	California	92115	—
Not listed	San Francisco	California	11355	—
Not listed	Miami	Florida	33136	—
Not listed	Detroit	Michigan	48202	—
Not listed	Manhasset	New York	11030	—
Not listed	New York	New York	10021	—
Not listed	New York	New York	10029-6574	—
Not listed	Germantown	Tennessee	38138	—
Not listed	Seattle	Washington	98111	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00507507, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 16, 2015 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00507507 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →